logo
Twitter
Discord
Email
logo
Mettler-Toledo International Inc.

Mettler-Toledo International Inc.

NYSE•MTD
CEO: Mr. Patrick K. Kaltenbach
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1997-11-14
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.
Contact Information
1900 Polaris Parkway, Columbus, OH, 43240, United States
614-438-4511
www.mt.com
Market Cap
$28.95B
P/E (TTM)
34.9
36.2
Dividend Yield
--
52W High
$1.53K
52W Low
$946.69
52W Range
81%
Rank19Top 4.0%
6.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$1.03B+7.87%
4-Quarter Trend

EPS

$10.60+5.89%
4-Quarter Trend

FCF

$274.88M+17.85%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Quarterly Sales Increased 8% Total net sales reached $1.030 B for the three months ended September 30, 2025, showing 8% growth in U.S. dollars.
Quarterly Net Earnings Up Net earnings for the quarter grew to $217.5M in 2025, resulting in basic EPS of $10.60 compared to $10.01.
Operating Cash Flow Increased Cash provided by operating activities totaled $730.2M for nine months 2025, up from $702.2M last year, despite higher incentives.
Q3 Acquisitions Completed Company completed several acquisitions in Q3 2025, involving $72.6M initial cash payments and $48.4M goodwill recorded.

Risk Factors

Escalating Tariff Costs Risk Escalating global trade disputes may result in estimated $50M incremental tariff costs during 2025, potentially impacting financial results.
Gross Margin Pressure Noted Gross profit margin compressed to 59.2% for the quarter, primarily reflecting increased tariff costs and unfavorable business mix.
Nine Month Earnings Decline Nine month net earnings declined to $583.4M in 2025 from $610.8M in 2024, driven by lower sales volume recovery timing.
Currency Fluctuation Exposure Earnings face risk from currency fluctuations; 1% Swiss franc strengthening against the euro could reduce annual earnings before tax by $2.6M.

Outlook

Share Buyback Boosted Board authorized an additional $2.75 B for share repurchase program in November 2025, funded by cash and borrowings.
Sufficient Liquidity Maintained Liquidity is deemed sufficient, supported by $472.4M available under the Credit Agreement and current cash balances as of September 30.
Contingent Acquisition Payments Future acquisition consideration up to $31.2M may be required based on financial thresholds over one to three years post-closing.

Peer Comparison

Revenue (TTM)

Humana Inc.HUM
$126.36B
+9.9%
IQVIA Holdings Inc.IQV
$15.90B
+3.8%
Labcorp Holdings Inc.LH
$13.77B
+8.3%

Gross Margin (Latest Quarter)

Natera, Inc.NTRA
64.9%
+3.1pp
DexCom, Inc.DXCM
60.5%
+0.8pp
Mettler-Toledo International Inc.MTD
59.2%
+1.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
A$39.21B30.020.6%26.4%
IQV$38.49B30.021.4%52.9%
NTRA$32.51B-104.5-25.1%10.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.5%
Flat Growth
4Q Net Income CAGR
-4.8%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 5, 2026
|
EPS:$12.76
|
Revenue:$1.10B
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 7, 2025|
    Revenue: $1.03B+7.9%
    |
    EPS: $10.60+5.9%
    Meet
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 1, 2025|
    Revenue: $983.22M+3.9%
    |
    EPS: $9.77-6.2%
    Meet
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 2, 2025|
    Revenue: $883.74M-4.6%
    |
    EPS: $7.84-5.3%
    Meet
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 7, 2025|
    Revenue: $3.87B+2.2%
    |
    EPS: $40.67+12.7%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $954.54M+1.3%
    |
    EPS: $10.01+8.1%
    Meet
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 2, 2024|
    Revenue: $946.75M-3.6%
    |
    EPS: $10.42+6.9%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 10, 2024|
    Revenue: $925.95M-0.3%
    |
    EPS: $8.28-2.9%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 9, 2024|
    Revenue: $3.79B-3.4%
    |
    EPS: $36.10-6.9%
    Beat